Drug updates and approvals: 2016 in review

Lindsy Meadowcraft; Geoffrey Mospan; Taylor Morrisette; Katie Smart; Melissa Janis

doi:10.1097/01.NPR.0000508167.22111.34

Drug updates and approvals: 2016 in review

Nurse Pract. 2016 Dec 16;41(12):20-27. doi: 10.1097/01.NPR.0000508167.22111.34.

Authors

Lindsy Meadowcraft¹, Geoffrey Mospan, Taylor Morrisette, Katie Smart, Melissa Janis

Affiliation

¹ Lindsy Meadowcraft is an assistant professor, ambulatory care pharmacy at Wingate University, School of Pharmacy, Hendersonville, N.C. Geoffrey Mospan is an assistant professor, internal medicine at Wingate University School of Pharmacy, Wingate, N.C. Taylor Morrisette is a pharmD candidate at Wingate University, School of Pharmacy, Hendersonville, N.C. Katie Smart is a pharmD candidate at Wingate University, School of Pharmacy, Hendersonville, N.C. Melissa Janis is a pharmD candidate at Wingate University, School of Pharmacy, Hendersonville, N.C.

PMID: 27861265
DOI: 10.1097/01.NPR.0000508167.22111.34

Abstract

In 2016, the FDA approved several new drugs for use in primary care. These drugs include amphetamine extended-release orally disintegrating tablets (Adzenys XR-ODT), elbasvir and grazoprevir (Zepatier), emtricitabine and tenofovir alafenamide (Descovy), glycopyrrolate and formoterol (Bevespi Aerosphere), insulin degludec injection (Tresiba), and ixekizumab (Taltz).